Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXCL7 siRNA
- Development stage
- Unknown
- Lead developer
- Barbara Ann Karmanos Cancer Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
CXCL7 siRNA is a small interfering RNA designed to silence the expression of C-X-C motif chemokine ligand 7 (CXCL7, also known as pro-platelet basic protein or PPBP). It is primarily used as a research reagent in preclinical oncology studies to investigate the role of the CXCL7/CXCR2 signaling axis in tumor cell proliferation, migration, invasion, and metastasis. Silencing CXCL7 with this siRNA has been shown to decrease heparanase activity and inhibit the invasion of various cancer cell types, including breast cancer and cholangiocarcinoma, through extracellular matrices.
- Other names
- CXCL7 small interfering RNACXCL-7 small interfering RNACXCL 7 small interfering RNAPPBP siRNApro-platelet basic protein siRNA
02
Targets
CXCL7 (C-X-C motif chemokine ligand 7)
Beyond the preview
Go deeper on CXCL7 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXCL7 siRNA.